The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Dedov I.I.

Endocrinology Research Centre

Melnichenko G.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

Belaia Zh.E.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva

Rozhinskaia L.Ia.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX-XXI centuries

Authors:

Dedov I.I., Melnichenko G.A., Belaia Zh.E., Rozhinskaia L.Ia.

More about the authors

Journal: Problems of Endocrinology. 2011;57(1): 35‑45

Read: 6684 times

Download PDF (RU)
Contact the author
Table of contents

OSTEOPOROSIS: FROM A RARE SYMPTOM OF ENDOCRINE DISEASES TO THE TACIT EPIDEMIC OF XX-XXI CENTURIES
OSTEOPOROSIS: FROM A RARE SYMPTOM OF ENDOCRINE DISEASES TO THE TACIT EPIDEMIC OF XX-XXI CENTURIES

To cite this article:

Dedov II, Melnichenko GA, Belaia ZhE, Rozhinskaia LIa. Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX-XXI centuries. Problems of Endocrinology. 2011;57(1):35‑45. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

This article describes the history of knowledge management with special reference to primary and secondary osteoporosis, its epidemiology and diagnostics of different forms of this disease. The discussion is focused on therapeutic modalities for the treatment of osteoporosis based on the principles of evidence-based medicine. Special attention is given to the choice of optimal medicinal preparations for the management of primary osteoporosis taking into account results of multicenter randomized placebo-controlled clinical studies and the results of evaluation of the efficacy of various pharmaceutical for the treatment of secondary osteoporosis and its mixed forms. Some of these studies are carried out based at the Endocrinological Research Centre. Peculiarities of analysis of their results are discussed along with comparative characteristics of selected pharmaceuticals.

Keywords:

primary and secondary osteoporosis
absolute risk of fracture
relative risk of fracture
biophosphonates

Authors:

Dedov I.I.

Endocrinology Research Centre

Melnichenko G.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

Belaia Zh.E.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva

Rozhinskaia L.Ia.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Close metadata

References:

  1. Schapira D., Schapira C. Osteoporosis: the evolution of a scientific term. Osteoporos Int 1992;2:4:164-167.
  2. Recklinghausen F.D. Die fibrose oder deformierende ositis, die osteomalazie und die osteoplastische carzinose in ihren gegenseitigen beziehungen. Festchrift Rudolf Virchow. George Reimer. Berlin 1891;1.
  3. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932;50:137-195.
  4. Kanis J.A., Johnell O., Oden A. et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000;11:8:669-674.
  5. Rizzoli R. Atlas of postmenopausal osteoporosis. 3-rd Ed. Curr Med Group 2010;33-60.
  6. O'Neill T.W., Felsenberg D., Varlow J. et al. The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:7:1010-1018.
  7. Cooper C., Atkinson E.J., Jacobsen S.J. et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:9:1001-1005.
  8. Bliuc D., Nguyen N.D., Milch V.E. et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:5:513-521.
  9. Cooper C. The crippling consequences of fractures and their consequences impact on quality of life. Am J Med 1997;103:2A:12S-17S.
  10. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:12:1726-1733.
  11. Cakir B., Odabasi E., Turan M. et al. Secondary osteoporosis in women. Arch Gynecol Obstet 2002;266:4:214-217.
  12. Dedov I.I., Rozhinskaya L.Ya. Mokrysheva N.G., Vasil'eva T.O. Etiologiya, patogenez, klinicheskaya kartina, diagnostika i lechenie pervichnogo giperparatireoza. Osteoporoz i osteopatii 2010;1:13-18.
  13. Rozhinskaya L.Ya. Sovremennye predstavleniya ob etiologii, klinicheskoi kartine, diagnostike i lechenii pervichnogo giperparatireoza. Lechashchii vrach 2009;3:15-20.
  14. Rozhinskaya L.Ya. Osteopenicheskii sindrom pri zabolevaniyakh endokrinnoi sistemy i postmenopauzal'nyi osteoporoz (patogeneticheskie aspekty, diagnostika i lechenie): Avtoref. dis. … d-ra med. nauk. M 2001.
  15. Sipina L.V. Otsenka minaral'noi plotnosti kostnoi tkani i pokazatelei kostnogo metabolizma u zhenshchin s diffuznym toksicheskim zobom: Avtoref. dis. … kand. med. nauk. M 2003.
  16. Ben-Shlomo A., Hagag P., Evans S., Weiss M. Early postmenopausal bone loss in hyperthyroidism. Maturitas 2001;39:1:19-27.
  17. Harvey C.B., O'Shea P.J., Scott A.J. et al. Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol Genet Metab 2002;75:1:17-30.
  18. Jódar E., Muñoz-Torres M., Escobar-Jiménez F. et al. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clin Endocrinol (Oxford) 1997;47:3:279-285.
  19. Vestergaard P., Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk - a meta-analysis. Thyroid 2003;13:6:585-593.
  20. Cummings S.R., Nevitt M.C., Browner W.S. et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:12:767-773.
  21. Bauer D.C., Nevitt M.C., Ettinger B., Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 1997;82:9:2931-2936.
  22. Kim D.J., Khang Y.H., Koh J.M. et al. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin Endocrinol (Oxford) 2006;64:1:86-90.
  23. Morris M.S. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 2007;40:4:1128-1134.
  24. Jamal S.A., Leiter R.E., Bayoumi A.M. et al. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int 2005;16:5:534-540.
  25. Lee W.Y., Oh K.W., Rhee E.J. et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 2006;37:4:511-516.
  26. Novack D.V. TSH, the bone suppressing hormone. Cell 2003;115:2:129-130.
  27. Sun L., Davies T.F., Blair H.C. et al. TSH and bone loss. Ann N Y Acad Sci 2006;1068:309-318.
  28. Tsai J.A., Janson A., Bucht E. et al. Weak evidence of thyrotropin receptors in primary cultures of human osteoblast-like cells. Calcif Tissue Int 2004;74:5:486-491.
  29. Deure V.W.M., Uitterlinden A.G., Pols H.A.P. et al. The TSH receptor ASP727GLU polymorphism is associated with higher bone mineral density and bone mineral content. Thyroid 2005;15:20-21.
  30. Abe E., Marians R.C., Yu W. et al. TSH is a negative regulator of skeletal remodeling. Cell 2003;115:2:151-162.
  31. Riggs B.L., Khosla S., Melton L.J. 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:3:279-302.
  32. Belaya Zh.E., Mel'nichenko G.A., Rozhinskaya L.Ya. i dr. Mineral'naya plotnost' kostnoi tkani i pokazateli kostnogo metabolizma u zhenshchin v menopauze s subklinicheskim tireotoksikozom razlichnogo geneza. Osteoporoz i osteopatii 2006;1:13-17.
  33. Morimura T., Tsunekawa K., Kasahara T. et al. Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005;146:4:2077-2084.
  34. Bianco A.C., Salvatore D., Gereben B. et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23:1:38-89.
  35. Baldini M., Gallazzi M., Orsatti A. et al. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Int Med 2002;251:5:407-414.
  36. Quan M.L., Pasieka J.L., Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 2002;79:1:62-69.
  37. Schneider R., Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabet 2003;111:8:455-470.
  38. Zelmanovitz F., Genro S., Gross J.L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998;83:11:3881-3885.
  39. Janghorbani M., Van Dam R.M., Willett W.C., Hu F.B. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:5:495-505.
  40. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis Osteoporos. Int 2007;18:4:427-444.
  41. Vestergaard P., Rejnmark L., Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009;84:1:45-55.
  42. Rozhinskaya L.Ya. Narusheniya mineral'nogo obmena, kostnogo metabolizma i ikh korrektsiya pri bolezni Itsenko-Kushinga: Avtoref. dis. ... kand. med. nauk. M 1991.
  43. Belaya Z., Sosunova N., Rozhinskaya L. et al. Fractures and bone remodeling in patients with endogenous hypercorticism. Abstract book of European Neuroendocrine Association 22-25 September 2010. Liege (Belgium) 2010;117.
  44. Lesnyak O.M., Benevolenskaya L.I. Rossiiskie klinicheskie rekomendatsii: Osteoporoz. Diagnostika, profilaktika i lechenie. M 2009;225-251.
  45. Füto L., Toke J., Patócs A. et al. Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome. Osteoporos Int 2008;19:7:941-949.
  46. Barahona M.J., Sucunza N., Resmini E. et al. Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. J Bone Miner Res 2009;24:11:1841-1846.
  47. Pivonello R., De Martino M.C., De Leo M. et al. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metab 2007;51:8:1381-1391.
  48. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series. WHO 1994;843:1-129.
  49. Kanis J.A., Burlet N., Cooper C. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:4:399-428.
  50. Kanis J.A., Johansson H., Oden A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:6:893-899.
  51. Belaya Zh.E., Rozhinskaya L.Ya., Sosunova N.V. Al'fakal'tsidol (Al'fa D3-Teva) - preparat s mnogokomponentnym deistviem na snizhenie riska perelomov. Osteoporoz i osteopatii 2008;1:22-28.
  52. Belaya Zh.E., Rozhinskaya L.Ya. Padeniya - vazhnaya sotsial'naya problema pozhilykh lyudei. Osnovnye mekhanizmy razvitiya i puti preduprezhdeniya. Rus med zhurn 2009;17:1614-1619.
  53. Meunier P.J., Roux C., Seeman E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:5:459-468.
  54. Reginster J.Y., Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:5:2816-2822.
  55. Recker R.R., Marin F., Ish-Shalom S. et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009;24:8:1358-1368.
  56. Blake G.M., Compston J.E., Fogelman I. Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Miner Res 2009;24:8:1354-1357.
  57. Li C., Paris O., Siegel S. et al. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res 2010;25:5:968-975.
  58. Belaya Zh.E., Rozhinskaya L.Ya., Belyaeva A.V., Mel'nichenko G.A. Novye vozmozhnosti lecheniya postmenopauzal'nogo osteoporoza: strontsiya ranelat (bivalos). Probl endokrinol 2006;52:5:47-55.
  59. Belaya Zh.E., Rozhinskaya L.Ya. Vozmozhnosti primeneniya paratireoidnogo gormona dlya lecheniya osteoporoza. Osteoporoz i osteopatii 2004;3:26-33.
  60. Belaya Zh.E., Rozhinskaya L.Ya. Sosunova N.V. Rol' faktorov riska v diagnostike osteoporoza i prinyatii resheniya o naznachenii terapii. Effektivnost' bisfosfonatov v lechenii osteoporoza. Rus med zhurn 2009;17:706-711.
  61. Belaya Zh.E., Rozhinskaya L.Ya., Mel'nichenko G.A. Ibandronat (Bonviva) - novoe napravlenie v lechenii bisfosfonatami. Luchshaya priverzhennost' k lecheniyu - luchshii rezul'tat. Osteoporoz i osteopatii 2006;3:23-29.
  62. Dedov I.I., Rozhinskaya L.Ya., Belaya Zh.E. Rol' i mesto bisfosfonatov v profilaktike i lechenii osteoporoza 10-letnii opyt primeneniya alendronata. Osteoporoz i osteopatii 2005;1:20-30.
  63. Lyles K.W., Colón-Emeric C.S., Magaziner J.S. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:18:1799-1809.
  64. McClung M., Miller P., Recknor C. et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009;114:5:999-1007.
  65. Barratt A., Wyer P.C., Hatala R. et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:4:353-358.
  66. Chesnut C.H. III, Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:8:1241-1249.
  67. Eisman J.A., Civitelli R., Adami S. et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:3:488-497.
  68. Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:5:654-661.
  69. Wilkes M.M., Navickis R.J., Chan W.W., Lewiecki E.M. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int 2010;21:4:679-688.
  70. O'Donnell S., Moher D., Thomas K. et al. Strontium ranelate for preventing and treating osteoporosis. The Cochrane Library 2008; Issue 4:CD005326. DOI: 10.1002/14651858.CD005326.pub3.
  71. O'Donnell S., Moher D., Thomas K. et al. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 2008;26:6:531-542.
  72. Ringe J.D., Dorst A., Faber H. et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14:10:801-807.
  73. Fahrleitner-Pammer A., Piswanger-Soelkner J.C., Pieber T.R. et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009;24:7:1335-1344.
  74. Belaya Zh.E., Rozhinskaya L.Ya., Kolesnikova G.S. i dr. Opyt primeneniya profilakticheskoi dozy alendronata (fosamaks 35 mg) dlya lecheniya osteoporoza u zhenshchin v postmenopauze s subklinicheskim tireotoksikozom. Osteoporoz i osteopatii 2007;1:12-19.
  75. Belaya Zh.E., Rozhinskaya L.Ya., Il'in A.V. i dr. Effektivnost' profilaktiki osteopenii preparatami kal'tsiya i vitamina D (Kal'tsii D3 Nikomed forte) u zhenshchin v postmenopauze s subklinicheskim tireotoksikozom. Osteoporoz i osteopatii 2007;2:13-18.
  76. Sosunova N.V., Belaya Z.E., Dzeranova L.K. et al. The comparative response of biochemical parameters concerning treatment with zoledronic acid 5mg a year in patients with primary hyperparathyroidism and postmenopausal osteoporosis. Osteoporos Int 2010;21:Suppl 1:158-159.
  77. Zaki M.E., Hussien F.H., Banna R.A. Osteoporosis among ancient Egyptians. Int J Osteoarvhaeol 2009;19:78-89.
  78. Cooper A., Drake J., Brankin E. PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:8:896-905.
  79. Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:9041:1535-1541.
  80. Cummings S.R., Black D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:24:2077-2082.
  81. Black D.M., Delmas P.D., Eastell R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:18:1809-1822.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.